3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide and Diseases in Twins

3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide has been researched along with Diseases in Twins in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Coppola, R; Gorey, JG; Hyde, TM; Jones, DW; Knable, MB; Lee, KS; Weinberger, DR; Wolf, SS	1

Other Studies

1 other study(ies) available for 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide and Diseases in Twins

Article	Year
Tourette syndrome: prediction of phenotypic variation in monozygotic twins by caudate nucleus D2 receptor binding. Science (New York, N.Y.), 1996, Aug-30, Volume: 273, Issue:5279 Topics: Adult; Benzamides; Caudate Nucleus; Diseases in Twins; Dopamine Antagonists; Female; Humans; Male; Phenotype; Putamen; Pyrrolidines; Receptors, Dopamine D2; Tomography, Emission-Computed, Single-Photon; Tourette Syndrome; Twins, Monozygotic	1996

Article

Year

Tourette syndrome: prediction of phenotypic variation in monozygotic twins by caudate nucleus D2 receptor binding.

Science (New York, N.Y.), 1996, Aug-30, Volume: 273, Issue:5279

Topics: Adult; Benzamides; Caudate Nucleus; Diseases in Twins; Dopamine Antagonists; Female; Humans; Male; Phenotype; Putamen; Pyrrolidines; Receptors, Dopamine D2; Tomography, Emission-Computed, Single-Photon; Tourette Syndrome; Twins, Monozygotic

1996